GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cadrenal Therapeutics
The shares of Cadrenal, a biotech company developing drugs to treat kidney disease, reflect the potential of its lead candidate. The price trajectory is a venture bet on success in clinical trials.
Share prices of companies in the market segment - Pharma kidney
Cadrenal Therapeutics is a pharmaceutical company developing a new anticoagulant for patients with kidney disease who are unsuitable for standard medications. We've categorized the company under "Pharma: Kidney." The chart below shows how the market is evaluating solutions for specific patient groups.
Broad Market Index - GURU.Markets
Cadrenal Therapeutics is a biopharmaceutical company focused on developing anticoagulants for patients with kidney disease. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
CVKD - Daily change in the company's share price Cadrenal Therapeutics
For Cadrenal Therapeutics, Inc., which develops drugs to treat kidney diseases, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma kidney
Cadrenal Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with CVKD, which focuses on kidney disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cadrenal Therapeutics is a biotech company specializing in the treatment of kidney diseases. Its shares are driven by news of clinical trials. This high volatility, driven by hopes, is a significant component of the overall "noise" and stock market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cadrenal Therapeutics
For Cadrenal Therapeutics, the year-over-year trend is a story about developing a new anticoagulant for patients with kidney disease. Its 12-month profitability depends entirely on progress in clinical trials. The success of its drug could offer a safer alternative to existing blood thinners for this vulnerable group of patients.
Annual dynamics of market capitalization of the market segment - Pharma kidney
As an early-stage biotech, Cadrenal is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its kidney disease drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cadrenal Therapeutics is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cadrenal Therapeutics
Cadrenal Therapeutics is a biopharmaceutical company focused on cardiovascular diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of trial results for its lead drug is the primary driver.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
Cadrenal Therapeutics is a pharmaceutical company focused on developing a drug to prevent thrombosis in patients with kidney disease. This is a specific and important niche. The dynamics of the pharmaceutical sector provide a general backdrop against which Cadrenal is trying to prove that its drug can become a new standard of care for this vulnerable group of patients.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing a new anticoagulant for patients with kidney disease. The company's future depends on the success of its clinical trials and regulatory approvals. The broader market chart serves only as a backdrop to understand how its potential to solve an important medical problem impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cadrenal Therapeutics
Cadrenal Therapeutics, focused on developing a drug to prevent blood clots in patients with kidney disease, is very sensitive to news. Its weekly stock price reflects progress in clinical trials, regulatory decisions, and any news about potential partnerships for further commercialization.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Cadrenal Therapeutics operates in the highly competitive cardiology sector, where investor sentiment drives global trends. The success or failure of a major blockbuster drug influences expectations for all companies in this niche. The chart below shows how CVKD fares in this competitive landscape compared to other developers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cadrenal Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how CVKD shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
CVKD - Market capitalization of the company Cadrenal Therapeutics
Cadrenal Therapeutics' market cap reflects a focused bet on kidney disease treatment. This pharmaceutical company's stock price reflects investor expectations for its sole drug candidate. Its dynamics directly reflect the market's response to each step in clinical trials and its assessment of its potential in this important medical niche.
CVKD - Share of the company's market capitalization Cadrenal Therapeutics within the market segment - Pharma kidney
Cadrenal Therapeutics is a biotech company focused on developing a new anticoagulant for patients with kidney disease. Its market share is based on this unmet medical need. The chart shows how the market perceives its potential to offer a safer alternative to existing medications.
Market capitalization of the market segment - Pharma kidney
Cadrenal Therapeutics is focused on developing a drug to prevent thrombosis in patients with kidney disease. The chart below shows the pharmaceutical sector's market capitalization. This represents a market where solving a specific medical problem could save thousands of lives.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cadrenal Therapeutics is a biopharmaceutical company developing a new anticoagulant for patients with kidney disease. Its market capitalization reflects the potential of its drug in this important niche. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
CVKD - Book value capitalization of the company Cadrenal Therapeutics
Cadrenal Therapeutics' book value represents the capital needed to develop a single drug. Its foundation is the licensing rights to tebacipril, a kidney disease drug, and the funds needed to advance it through clinical trials. The chart below shows how the company is accumulating resources to bring this targeted drug to market.
CVKD - Share of the company's book capitalization Cadrenal Therapeutics within the market segment - Pharma kidney
Cadrenal Therapeutics relies on research laboratories to develop kidney drugs. The S_BCap_Seg graph shows its minimal share of the pharmaceutical sector's physical infrastructure, which is typical for a company in the clinical development stage.
Market segment balance sheet capitalization - Pharma kidney
Cadrenal Therapeutics is a biotech company focused on drugs for the treatment of heart and kidney diseases. At this stage, its main asset is intellectual property. The chart will show how "light" its balance sheet is, with value being driven by scientific developments rather than production assets.
Book value of all companies included in the broad market index - GURU.Markets
Cadrenal Therapeutics' book value represents capital focused on kidney protection. The company's assets primarily include the license to develop the drug tecarfarin and the financial resources to advance it through clinical trials. The chart shows the size of its financial base dedicated to developing a safe anticoagulant for patients with kidney disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cadrenal Therapeutics
Cadrenal Therapeutics is focused on developing a drug for patients with kidney disease. The company's book value is low. Its market capitalization reflects investors' bet on the success of its sole drug candidate in clinical trials and its potential to fill an important niche in cardiorenal medicine.
Market to book capitalization ratio in a market segment - Pharma kidney
Cadrenal Therapeutics is a clinical-stage biotech company developing treatments for patients with kidney disease. The chart shows how the market values the potential of its lead candidate, placing a premium on its book value, which primarily reflects its available cash.
Market to book capitalization ratio for the market as a whole
Cadrenal Therapeutics is a biopharmaceutical company developing treatments for people with kidney disease. Its value is determined solely by the potential of its single drug candidate. The chart shows how the market valuation reflects investors' confidence in the success of clinical trials, rather than their current tangible assets.
Debts of the company, segment and market as a whole
CVKD - Company debts Cadrenal Therapeutics
Cadrenal Therapeutics, a biopharmaceutical company focused on kidney diseases, relies entirely on external financing. This chart illustrates how it raised debt or convertible equity to advance its lead candidate through the rigorous and costly stages of clinical trials. Debt here is a bridge to potential FDA approval.
Market segment debts - Pharma kidney
Cadrenal Therapeutics is a biotech company focused on developing a treatment for people with kidney disease. Currently in clinical trials, the company has no sales revenue. Its survival depends entirely on effective cash management. This chart shows its financial headroom for continued development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cadrenal Therapeutics
Cadrenal Therapeutics is a biotech company focused on kidney disease treatments. This chart reflects its debt policy. In the biotech industry, where research requires millions of dollars, reliance on debt is critical. It illustrates the company's risk in pursuing regulatory approval for its developments.
Market segment debt to market segment book capitalization - Pharma kidney
Cadrenal Therapeutics is a clinical-stage company developing drugs for patients with kidney disease. This biotech industry chart illustrates how the sector as a whole finances the long and risky path from lab to pharmacy. It provides context for assessing the company's financial strategy and sustainability.
Debt to book value of all companies in the market
Cadrenal Therapeutics is focused on developing a drug for patients with kidney disease and heart failure who require anticoagulants. The presented debt-to-book value ratio reflects the overall risk appetite in the pharmaceutical industry. Cadrenal's success depends on the availability of capital to conduct costly clinical trials.
P/E of the company, segment and market as a whole
P/E - Cadrenal Therapeutics
Cadrenal Therapeutics is focused on developing a new anticoagulant for patients with kidney disease. This chart reflects investors' confidence in the company's ability to fill an important medical niche. Its significance indicates the market's willingness to invest in the potential success of a drug that could become a safer alternative for a vulnerable patient group.
P/E of the market segment - Pharma kidney
Cadrenal Therapeutics, like Akari, operates in the biotech sector. This chart shows the industry's average valuation, based on future expectations. Comparing the company's P/E ratio to this benchmark allows us to understand whether investors consider its niche (drugs for kidney patients) more or less promising than other biotech sectors.
P/E of the market as a whole
Cadrenal Therapeutics is focused on developing a drug to prevent blood clots in patients with kidney disease. This is a niche but important market. The company's success depends entirely on clinical and regulatory results. This chart reflects the overall sentiment in the pharmaceutical industry. It allows one to assess how the market perceives the success of the company's single drug compared to the overall industry.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage company focused on developing an anticoagulant for patients with kidney disease. The chart shows investor expectations for future revenue, which depend on successful completion of clinical trials and regulatory approval for entry into this highly specialized market.
%20P%2FE%20Cadrenal%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cadrenal-Therapeutics&v=1772668064612 "Chart of the company's future (projected) P/E Cadrenal Therapeutics")
Future (projected) P/E of the market segment - Pharma kidney
Cadrenal Therapeutics is focused on developing a drug to prevent blood clots in patients with kidney disease. This chart shows how its future revenue expectations compare to the pharmaceutical industry average, reflecting the potential of its niche drug to address a serious medical need.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772668064656 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
Cadrenal Therapeutics is a biopharmaceutical company focused on developing a drug to prevent thrombosis in patients with kidney disease. Its valuation is based on the success of clinical trials for a specific patient group. It is not dependent on general market sentiment, but rather is determined by science.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772668064684 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cadrenal Therapeutics
Cadrenal Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of cardiovascular and renal diseases. Being in the clinical trials stage, its financial indicators primarily reflect R&D expenses. This chart illustrates the financial investments required to bring a new drug to market.
Profit of companies in the market segment - Pharma kidney
Cadrenal Therapeutics is a biopharmaceutical company focused on developing a drug to prevent thrombosis in patients with kidney disease. This chart shows the profitability of its narrow segment. Being in the research stage, the company is not yet profitable, but its potential success could create a new standard of treatment and radically change the overall profitability landscape.
Overall market profit
Cadrenal Therapeutics is a biotech company focused on developing treatments for patients with kidney and cardiovascular diseases. Its success is not tied to economic cycles, but rather depends on scientific breakthroughs and regulatory approvals. This chart illustrates the overall market trend, against which Cadrenal is addressing specific and important medical needs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cadrenal Therapeutics
Cadrenal Therapeutics is focused on developing a drug to prevent blood clots in patients with kidney disease. The company's future profits, projected in this chart, are entirely dependent on the success of clinical trials and subsequent regulatory approval. It is an indicator of analysts' expectations regarding the potential of this niche drug.
%20profit%20of%20the%20company%20Cadrenal%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cadrenal-Therapeutics&v=1772668064795 "Graph of future (projected) profit of the company Cadrenal Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma kidney
Cadrenal Therapeutics is a biopharmaceutical company focused on developing an anticoagulant for patients with kidney disease. This chart shows profitability projections for the renal pharmaceutical segment. It illustrates expectations for new treatments for vulnerable patient groups, where Cadrenal aims to carve out a niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772668064827 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
Cadrenal Therapeutics focuses on drugs for patients with kidney disease. For such companies, the key factor is not so much the current economic climate as the availability of capital for lengthy and expensive clinical trials. The overall market profit forecast influences investor willingness to finance biotech companies, which is critical for Cadrenal's future.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772668064836 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cadrenal Therapeutics
Cadrenal Therapeutics is a biotech company focused on drugs for patients with kidney disease. Before a product's commercialization, the P/S ratio is uninformative. However, after market launch, it will become a key indicator of the premium investors are willing to pay for the first few dollars of sales, anticipating a solution to an important medical problem.
P/S market segment - Pharma kidney
Cadrenal Therapeutics is a biotech company focused on developing a new anticoagulant for patients with kidney disease. The potential market for such a drug is significant. This chart shows how the market views the scientific potential of their lead candidate and future revenue streams in this specific and important medical niche.
P/S of the market as a whole
Cadrenal Therapeutics is a biotech company focused on developing a treatment for patients with kidney disease. The company has no commercial revenue, and its value is based on the potential of one key asset. This chart, showing the valuation of companies with actual revenue, highlights the speculative nature of clinical-stage biotech investments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cadrenal Therapeutics
Cadrenal Therapeutics is a biotech company focused on developing a treatment for patients with kidney disease. Its value is determined by the prospects of this single asset. This chart reflects investor expectations for future revenue from sales of a drug that could fill an important niche in the treatment of this vulnerable patient group.
%20P%2FS%20Cadrenal%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cadrenal-Therapeutics&v=1772668064877 "The graph of the company's future (projected) P/S Cadrenal Therapeutics")
Future (projected) P/S of the market segment - Pharma kidney
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing a drug to prevent blood clots in patients with kidney disease. This chart shows how the market perceives the future potential of its niche product. It compares it to other pharmaceutical companies, reflecting investor expectations regarding the success of clinical trials and market entry.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772668064895 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
Cadrenal Therapeutics is a company focused on developing a new anticoagulant for patients with kidney disease. This is a highly specialized but important market in cardiology. This chart reflects overall revenue forecasts, and Cadrenal illustrates how pharmaceutical startups solving specific medical problems are shaping expectations for future growth in healthcare.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772668064905 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of cardiovascular and renal diseases. Currently, the company has no commercialized products, so its revenue on this graph is likely zero. Future revenue will depend on the success of clinical trials and drug approvals.
Sales of companies in the market segment - Pharma kidney
Cadrenal Therapeutics is a biotech company focused on drugs for the treatment of heart and kidney diseases. At this stage of development, its revenue may be derived from partnerships. This chart allows investors to assess financial support, which is an indicator of the credibility of its research.
Overall market sales
Cadrenal Therapeutics is a biotech company focused on therapeutics for patients with kidney disease. The need for effective treatments for chronic diseases is not dependent on the economic climate. This schedule is not a factor for Cadrenal, whose potential is determined by clinical results and unmet medical needs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage company focused on developing a drug to prevent thrombosis in patients with kidney disease. Its revenue forecast is based entirely on expectations of future clinical success. This chart shows analysts' speculative estimates of its potential in this important medical market.
%20sales%20of%20the%20company%20Cadrenal%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cadrenal-Therapeutics&v=1772668064953 "Schedule of future (projected) sales of the company Cadrenal Therapeutics")
Future (projected) sales of companies in the market segment - Pharma kidney
Cadrenal Therapeutics is focused on developing drugs to treat cardiovascular and renal diseases. This chart shows projected revenue for the kidney disease pharmaceutical segment. It allows for assessing potential demand for new treatments, which is critical for a company targeting this specific and large market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772668064957 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
Cadrenal Therapeutics is a biopharmaceutical company focused on developing treatments for patients with kidney disease. Its future depends on the success of clinical trials. This graph of general market expectations does not directly impact demand, but reflects the investment climate, which is critical for raising funds for long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772668064971 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage biotechnology company focused on developing drugs for the treatment of heart and kidney diseases. This chart reflects the company's R&D investment. The company's future profitability depends entirely on the success of clinical trials and the subsequent commercialization of its lead candidate.
Market segment marginality - Pharma kidney
Cadrenal Therapeutics focuses on developing drugs to treat cardiovascular and renal diseases that remain untreated. This chart shows the average profitability in the pharmaceutical sector specializing in kidney diseases. It allows one to estimate the level of profitability the company can expect if its developments are successful.
Market marginality as a whole
Cadrenal Therapeutics is also a biopharmaceutical company focused on treating kidney diseases. Its future depends entirely on the results of clinical trials and regulatory approval. This total market return chart shows the current situation, while Cadrenal's entire value is a bet on a future medical breakthrough.
Employees in the company, segment and market as a whole
Number of employees in the company Cadrenal Therapeutics
Cadrenal Therapeutics is a biotech company focused on developing a treatment for patients with kidney disease. At its current clinical stage, the team is very compact and consists of key specialists. This diagram illustrates the model where a small group of experts advances a single promising asset through the development stages.
Share of the company's employees Cadrenal Therapeutics within the market segment - Pharma kidney
Cadrenal Therapeutics is a biopharmaceutical company developing drugs for patients with kidney and cardiovascular diseases. This chart highlights its scientific focus. It shows the proportion of cardiologists, nephrologists, and researchers working on developing a new anticoagulant for this vulnerable group of patients who are part of Cadrenal.
Number of employees in the market segment - Pharma kidney
Cadrenal Therapeutics specializes in developing drugs for patients with kidney and cardiovascular diseases. This chart illustrates employment in nephrology pharmaceuticals. The growing number of specialists in this field indicates a high need for new treatments, as kidney diseases often lead to serious complications.
Number of employees in the market as a whole
Cadrenal Therapeutics develops drugs to treat kidney diseases. The pharmaceutical industry, especially at the clinical trial stage, is actively hiring scientists and medical professionals. This chart shows the overall employment profile of these highly specialized and critically important companies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics, focused on treating kidney disease, exemplifies the value of niche expertise. The market values each employee based on the potential of their developments in a narrow but important area of medicine. This graph illustrates the premium for intellectual capital focused on solving a specific medical problem.
%20of%20the%20company%20Cadrenal%20Therapeutics%20(CVKD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cadrenal-Therapeutics-CVKD&v=1772668065361 "Chart of market capitalization per employee (in thousands of dollars) of the company Cadrenal Therapeutics (CVKD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
Cadrenal Therapeutics is focused on drugs for kidney disease. Like many biotech companies, its value lies in its intellectual property. Its market value per employee reflects how investors view the potential of its developments. Its significant outperformance of the industry benchmark suggests expectations for breakthrough research from its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772668065383 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
Cadrenal Therapeutics is a biotech company focused on developing a treatment for patients with kidney disease. For clinical-stage companies, their value lies in their intellectual property and research data. This chart shows how the market values the potential of a small scientific team to solve an important medical problem.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772668065392 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics is a biotech company focused on developing drugs for the treatment of cardiovascular and renal diseases. It's a pure R&D business. At the clinical trial stage, this graph is naturally negative. It reflects the investment spent on each employee working on a future drug.
%20Chart%20Cadrenal%20Therapeutics%20(CVKD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cadrenal-Therapeutics-CVKD&v=1772668065408 "Company Profit Per Employee (in thousands of dollars) Chart Cadrenal Therapeutics (CVKD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
Cadrenal Therapeutics is focused on developing a treatment for kidney disease in patients with heart failure. This chart illustrates the cost effectiveness of their research strategy. It shows how targeted investment in a team of highly specialized specialists can lead to the creation of a valuable asset capable of generating high returns in the cardiorenal therapeutics sector.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772668065455 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
Cadrenal Therapeutics is a biopharmaceutical company specializing in kidney disease treatments. Like many biotechs without an approved product, this chart shows inverse efficiency—R&D spending per employee. The trend reflects the intensity of research and clinical trials before reaching profitability.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772668065468 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics, a biotech company in the drug development stage, is typical for the sector, showing zero or minimal revenue per employee. It reflects not current productivity but investment in future potential. Successful commercialization will lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cadrenal-Therapeutics-CVKD&v=1772668065500 "Sales chart per company employee Cadrenal Therapeutics (CVKD)")
Sales per employee in the market segment - Pharma kidney
Cadrenal Therapeutics (CVKD) is a biopharmaceutical company focused on developing treatments for kidney diseases, specifically an anticoagulant for patients with renal failure. This chart shows the average revenue per employee in the pharmaceutical segment. Being in the R&D stage, Cadrenal has no commercial sales. Comparison with the benchmark highlights their focus on development rather than current sales productivity.
Sales per employee for the market as a whole
Cadrenal Therapeutics is another clinical-stage biotech focused on kidney diseases. The company has no revenue. This metric is meaningless until the drug is approved. It merely illustrates the "cost" of research. Investors are focused entirely on trial data, which can convert personnel costs into future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics is a biotech startup trying to revive and commercialize a drug (Tecarfarin) for patients with kidney disease who require anticoagulants. This chart illustrates market skepticism. Bears are betting that the company will fail to prove the benefits of this "old-new" drug or will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cadrenal-Therapeutics-CVKD&v=1772668065549 "Short Shares Chart for the Company Cadrenal Therapeutics (CVKD)")
Shares shorted by market segment - Pharma kidney
Cadrenal Therapeutics is a biotech focused on developing treatments for patients with kidney and heart disease. This chart shows the overall bearish sentiment in the sector. The high short positioning across the industry may indicate that investors doubt the commercial potential of the drugs for this complex patient group or anticipate difficulties with clinical trials. This creates a background of mistrust for CVKD.
Shares shorted by the overall market
Cadrenal Therapeutics is focused on developing a drug for patients with kidney disease and arrhythmia. It's a highly specialized biotech. This chart measures overall market fear. At such times, investors prefer to cash out rather than take risks. Pre-profit biotech stocks like CVKD are the first to be hit by the sell-off, regardless of the scientific potential of their developments.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics (CVKD) specializes in drugs for the treatment of cardiovascular and kidney diseases. The company's success depends on the results of clinical trials. This indicator measures the rate of price change. It helps determine when the stock is "overheated" (above 70) due to data expectations or "oversold" (below 30) due to delays or profit-taking.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cadrenal-Therapeutics-CVKD&v=1772668065588 "RSI 14 indicator chart for the company's stock Cadrenal Therapeutics (CVKD)")
RSI 14 Market Segment - Pharma kidney
Cadrenal (CVKD) is a biotech company developing a new anticoagulant (blood thinner) for patients with kidney disease who are unsuitable for existing medications. This chart tracks overall sentiment in the Pharmaceuticals/Kidney Diseases sector. It helps differentiate CVKD's niche from the generally overheated or oversold biotech sector.
RSI 14 for the overall market
Cadrenal Therapeutics (CVKD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CVKD (Cadrenal Therapeutics)
Cadrenal (CVKD) is a biopharmaceutical company developing Tecarfarin, an oral anticoagulant (blood thinner) for patients with kidney failure. This chart shows the speculative average price target from analysts based on their belief in this niche but important R&D program.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CVKD-Cadrenal-Therapeutics&v=1772668065634 "A chart showing analyst consensus forecasts for the expected stock price. CVKD (Cadrenal Therapeutics)")
The difference between the consensus estimate and the actual stock price CVKD (Cadrenal Therapeutics)
Cadrenal Therapeutics is a biopharmaceutical company developing a new anticoagulant (blood thinner) for patients with kidney disease. This chart shows how much the current share price differs from the "fair" value predicted by analysts. It reflects their confidence in this important R&D program.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CVKD-Cadrenal-Therapeutics&v=1772668065652 "A chart showing the difference between the consensus forecast and the actual stock price. CVKD (Cadrenal Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
Cadrenal Therapeutics (CVKD) is a biotech company developing Tecarfarin, a next-generation anticoagulant (blood thinner) for patients with kidney failure. This chart shows general expectations for the kidney pharmaceutical sector. It reflects whether experts believe there is a market need for "safe" anticoagulants.
Analysts' consensus forecast for the overall market share price
Cadrenal Therapeutics (CVKD) is a clinical-stage biopharmaceutical company focused on treating cardiovascular diseases (thrombosis, arrhythmia). This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cadrenal Therapeutics
Cadrenal Therapeutics is a late-stage biotech company. Their main focus is the development of Tecarfarin, an anticoagulant (blood thinner) that they believe will work better than Warfarin in patients with kidney disease. This chart is a summary of their R&D progress. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of FDA approval.
AKIMA Market Segment Index - Pharma kidney
Cadrenal Therapeutics (CVKD) is a biopharmaceutical company focused on developing Tecarfarin, a next-generation anticoagulant (blood thinner) for patients with kidney disease and arrhythmia. The chart shows the average index for the segment, helping investors assess how this niche but important development compares to the average.
The AKIM Index for the overall market
Cadrenal Therapeutics is a biopharmaceutical company developing tecarfarin, an anticoagulant for patients with end-stage renal disease. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche cardiology company compares to overall economic trends.
